Skip Ribbon Commands
Skip to main content

Asst Prof Tham Chee Kian

Dr Tham Chee Kian from National Cancer Centre Singapore

Asst Prof Tham Chee Kian

MBBS (NUS), MMed (Internal Medicine) NUS

Deputy Head and Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology, Medical Oncology

Sub-specialties: Hepato-Pancreato-Biliary, Upper Gastrointestinal, Colorectal, Neuro-Oncology, Peritoneal-based Malignancies

Conditions Treated by this Doctor:
Colorectal Cancer, Hepato-Pancreato-Biliary Cancers, Neuro-oncology, Peritoneal based Malignancies, Upper Gastrointestinal Cancers.

Clinical Appointments

  • Deputy Head and Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Assistant Professor


Dr Tham Chee Kian is a Senior Consultant at the Department of Medical Oncology, National Cancer Centre Singapore (NCCS) and the medical director of the NCCS Oncology Clinic at Changi General Hospital. His subspecialty interest is in neuro-oncology and gastrointestinal oncology. He is also actively involved in medical education. He is currently an Assistant Professor at the Duke-NUS Medical School and is the course director for the Year 1 Duke-NUS Practice Course. He is also the Associate Program Director of the SingHealth Internal Medicine Residency Program.


  • MMed (Internal Medicine), National University of Singapore 
  • MBBS, National University of Singapore

Professional Appointments and Committee Memberships

  • Member, Fellowship of the Academy of Medicine, Singapore (FAMS) 
  • Member, Society of Neuro-Oncology 
  • Member, American Society of Oncology 
  • Member, Singapore Society of Oncology


  • Talent Development Fund Award in Masters of Medical Education, 2012 
  • Award for Clinician Investigator Salary Support Programme (CISSP) , 2011 
  • Singapore Health Quality Service Award, Silver, SingHealth, 2010 and 2011 
  • Best Registrar Award, SingHealth, 2007 and 2008

Research Interests


  • Tan G, Chia C, Kumar M, Choo SP, Chia J, Tham CK, Chua C, Soo KC, Teo M. 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. Int J Hyperthermia. 2016 Dec 14:1-7. [Epub ahead of print] 
  • Liu Y, Chew MH, Tham CK, Tang CL, Ong SY, Zhao Y. Methylation of serum SST gene is an independent prognostic marker in colorectal cancer. Am J Cancer Res. 2016 Sep 1;6(9):2098-2108. 
  • Tan GH, Kwek JW, Hosseini R, Chanyaputhipong J, Tham CK, Soo KC, Teo MC. Proposed radiological criteria for pre-operative determination of resectability in peritoneal-based malignancies. J Med Imaging Radiat Oncol. 2016 Jun;60(3):337-43. 
  • Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. Kusumawidjaja G, Gan PZ, Ong WS, Teyateeti, Dankulchai, Tan DY, Chua ET, Chua KL, Tham CK, Wong FY, Chua ML. Onco Targets Ther. 2016 Mar 2;9:1115-22. doi: 10.2147/OTT 
  • Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? Tan GH, Ong WS, Chia CS, Tham CK, Soo KC, Teo MC. Int J Hyperthermia. 2016 Feb 10:1-8. 
  • Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP. Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408. Epub 2015 Jun 24. 
  • Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. Chong DQ, Toh XY, Ho IA, Sia KC, Newman JP, Yulyana Y, Ng WH, Lai SH, Ho MM, Dinesh N, Tham CK*, Lam PY.BMC Cancer. 2015 Apr 11;15(1):255. doi: 10.1186/s12885-015-1191-3. (*Co-corresponding author) 
  • Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Tham CK, Chew M, Soong R, Lim J, Ang M, Tang C, Zhao Y, Ong SY, Liu Y. Cancer. 2014 Oct 15;120(20):3131-41. doi: 10.1002/cncr.28802. 
  • Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Van Cutsem E, Li CP, Nowara E, Aprile G, Moore M, Federowicz I, Van Laethem JL, Hsu C, Tham CK, Stemmer SM, Lipp R, Zeaiter A, Fittipaldo A, Csutor Z, Klughammer B, Meng X, Ciuleanu T. Br J Cancer. 2014 Sep 23. doi: 10.1038/bjc.2014.494. 
  • Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: The experience of a tertiary Asian center. Teo MC, Ching Tan GH, Lim C, Chia CS, Tham CK, Soo KC. Asian J Surg. 2014 Jul 21. 

Research Trials

  • A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification